Drugs / fondaparinux background and standard dose UFH
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00790907 | Feb 2009 → May 2010 | acute coronary syndrome | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | fondaparinux background and standard dose UFH | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00790907 ↗ |
| Route | Intravenous | “2 dose regimens of adjunctive intravenous UFH during PCI” PMID 21146654 ↗ Dec 2010 |